Iran as the world's 18th-most-populous country has passed 80 million in 2016 with its population growth rate of about 1.3. In 2013, it was reported that sixty percent of its population was under the age of 30. With an estimated Gross Domestic Product (GDP) in 2015 of 393.7 billion USD Iran is the second largest economy in the Middle East and North Africa (MENA) region. In addition, Iran has one of the largest capacity of production of generic medicines in the Middle East and MENA region. While per capita consumption of generic medicines is acceptable, access to specialized medicines for treatment of life threatening medicines is restricted due to limited resources available in health care system. Therefore, most imported medicines are including biotherapeutics, recombinants and oncology medicines. Of late, Iran MOH has announced its support for international investment into Iran pharmaceutical market. Iran plans to provide acceptable environment in order to attract foreign investment for pharmaceutical industry in order to upgrade its technology capabilities and manufacture high tech medicines such as mAbs and recombinant proteins.